Exchange Traded Concepts’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.09M Buy
40,368
+23,316
+137% +$1.19M 0.01% 600
2025
Q4
$847K Sell
17,052
-498
-3% -$24.2K 0.01% 878
2025
Q3
$839K Sell
17,550
-7,815
-31% -$315K 0.01% 841
2025
Q2
$800K Buy
25,365
+484
+2% +$15.5K 0.01% 767
2025
Q1
$815K Buy
24,881
+2,762
+12% +$97.9K 0.01% 642
2024
Q4
$800K Buy
22,119
+560
+3% +$19.7K 0.02% 658
2024
Q3
$672K Buy
+21,559
New +$673K 0.02% 703
2024
Q1
Sell
-42,189
Closed -$1.22M 1417
2023
Q4
$1.22M Buy
42,189
+335
+0.8% +$8.88K 0.03% 360
2023
Q3
$1.15M Buy
41,854
+26,390
+171% +$803K 0.03% 353
2023
Q2
$465K Sell
15,464
-510
-3% -$17.8K 0.01% 627
2023
Q1
$579K Sell
15,974
-3,964
-20% -$152K 0.02% 513
2022
Q4
$711K Buy
19,938
+540
+3% +$18.8K 0.02% 378
2022
Q3
$657K Sell
19,398
-74
-0.4% -$2.41K 0.02% 332
2022
Q2
$563K Buy
19,472
+444
+2% +$12.7K 0.02% 462
2022
Q1
$615K Sell
19,028
-27,607
-59% -$846K 0.01% 517
2021
Q4
$1.36M Buy
46,635
+813
+2% +$24.7K 0.03% 296
2021
Q3
$1.22M Buy
45,822
+9,717
+27% +$261K 0.03% 288
2021
Q2
$1.11M Buy
36,105
+3,433
+11% +$105K 0.04% 301
2021
Q1
$855K Buy
32,672
+4,362
+15% +$122K 0.03% 316
2020
Q4
$712K Buy
28,310
+2,760
+11% +$59.4K 0.03% 277
2020
Q3
$532K Buy
25,550
+4,414
+21% +$100K 0.03% 289
2020
Q2
$502K Buy
+21,136
New +$467K 0.08% 210

Other funds holding SUPN

Exchange Traded Concepts's SUPN Position: Q1 2026 in Review

Exchange Traded Concepts increased its Supernus Pharmaceuticals (SUPN) stake by 137% in Q1 2026, buying an estimated $1.19M and bringing the position to 40,368 shares worth $2.09M. The position accounts for 0.01% of the portfolio, ranked #600.

Exchange Traded Concepts first reported a position in SUPN in Q2 2020 and has held it in 22 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Exchange Traded Concepts held 40,368 shares of Supernus Pharmaceuticals worth $2.09M as of Q1 2026.
  • Exchange Traded Concepts bought 23,316 Supernus Pharmaceuticals shares in Q1 2026, an estimated $1.19M.
  • Supernus Pharmaceuticals made up 0.01% of Exchange Traded Concepts's portfolio in Q1 2026, its #600 holding.
  • Exchange Traded Concepts first reported a position in Supernus Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Exchange Traded Concepts's 13F filing for Q1 2026, filed 15 Apr 2026.